PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34905798-6 2021 When a germline mutation in the BRCA-2 gene could be identified, he took part in the POLO-study receiving a maintenance therapy with the PARP-Inhibitor Olaparib. olaparib 152-160 collagen type XI alpha 2 chain Homo sapiens 137-141 34897998-7 2022 Experimental analyses demonstrated that UBR5 associates with and downregulates two key DNA damage repair proteins (XRCC3 and FANCD2) and confers PC cell sensitivity to olaparib, a PARP inhibitor in clinical use for cancer therapy. olaparib 168-176 collagen type XI alpha 2 chain Homo sapiens 180-184 34722729-3 2021 The patient received a multimodal therapy including surgery, systemic chemotherapy, and targeted therapy with the PARP inhibitor olaparib, resulting in an overall survival of 47 months. olaparib 129-137 collagen type XI alpha 2 chain Homo sapiens 114-118 34680387-13 2021 Finally, 20 patients were treated with the PARP inhibitor olaparib based on the sequencing results. olaparib 58-66 collagen type XI alpha 2 chain Homo sapiens 43-47 34082024-1 2021 Olaparib, a potent PARP inhibitor, has been shown to have great anti-tumor effects in some tumor types. olaparib 0-8 collagen type XI alpha 2 chain Homo sapiens 19-23 34681173-6 2021 The substances synergized with the clinically approved PARP inhibitor olaparib and resensitized AR-V7-expressing PCa cells to antiandrogen enzalutamide, as well as to a combination of enzalutamide and an AKT inhibitor. olaparib 70-78 collagen type XI alpha 2 chain Homo sapiens 55-59 34900718-9 2021 Currently, two PARP inhibitors have been approved for triple negative metastatic breast cancer-olaparib and talazoparib-based on two phase III trials, which showed a progression-free survival benefit when compared to chemotherapy. olaparib 95-103 collagen type XI alpha 2 chain Homo sapiens 15-19 34475104-1 2021 PURPOSE: To assess the efficacy of olaparib, a PARP inhibitor (PARPi) in patients with tumors with BRCA1/2 mutations, regardless of histological tumor type. olaparib 35-43 collagen type XI alpha 2 chain Homo sapiens 47-51 34781271-3 2021 This uncommon finding in a patient with endometrial carcinoma provided the opportunity to use a management strategy of PARP inhibition with olaparib, resulting in a prolonged response to treatment; however, disease progression eventually occurred. olaparib 140-148 collagen type XI alpha 2 chain Homo sapiens 119-123 34572735-3 2021 Moreover, we demonstrated that inhibition of MDM2 expression diminished DNA repair by homologous recombination (HR) and sensitized SKBR3 cells to a PARP inhibitor, olaparib. olaparib 164-172 collagen type XI alpha 2 chain Homo sapiens 148-152 34457184-7 2021 Inhibitors of PARP (olaparib and talazoparib), PD-L1 (atezolizumab) and an antibody drug conjugate targeting Trop-2 (sacituzumab govitecan-hziy) are now approved for the use in select groups of patients with TNBC. olaparib 20-28 collagen type XI alpha 2 chain Homo sapiens 14-18 35326611-4 2022 Here, we showed that combining RT (photons and protons) to noncytotoxic concentration of PARP inhibitor, Olaparib, induced a cell line-dependent senescence-like phenotype. olaparib 105-113 collagen type XI alpha 2 chain Homo sapiens 89-93 34200245-3 2021 Olaparib, a PARP inhibitor, has been approved as maintenance for PDAC patients harboring germline BRCA1/2 pathogenic mutations and previously treated with a platinum-based chemotherapy. olaparib 0-8 collagen type XI alpha 2 chain Homo sapiens 12-16 35078817-0 2022 ATR inhibitor AZD6738 (ceralasertib) exerts antitumor activity as a monotherapy and in combination with chemotherapy and the PARP inhibitor olaparib. olaparib 140-148 collagen type XI alpha 2 chain Homo sapiens 125-129 35078817-7 2022 AZD6738 showed combinatorial efficacy with agents associated with replication fork stalling and collapse such as carboplatin and irinotecan and the PARP inhibitor olaparib. olaparib 163-171 collagen type XI alpha 2 chain Homo sapiens 148-152 34143979-1 2021 The combination of PD-L1 inhibitor durvalumab and PARP inhibitor olaparib added to standard paclitaxel neoadjuvant chemotherapy (durvalumab/olaparib/paclitaxel (DOP)) was investigated in the phase II I-SPY2 trial of stage II/III HER2-negative breast cancer. olaparib 65-73 collagen type XI alpha 2 chain Homo sapiens 50-54 34070674-8 2021 Recently, Olaparib (a PARP inhibitor) was approved for treatment of BRCA1/2 breast and ovarian cancer as the first successful synthetic lethality-based therapy, showing considerable success in the development of effective targeted cancer therapeutics. olaparib 10-18 collagen type XI alpha 2 chain Homo sapiens 22-26 34336608-8 2021 Conclusion: The current investigation focuses on designing a multifunctional drug delivery platform for concurrent delivery of either PAC or PARP inhibitor (olaparib) and FOXM1 siRNA in chitosan-coated poly(D, L-lactide-co-glycolide) (PLGA) nanoparticles (NPs) with the ability to emerge as a front runner therapeutic for TNBC therapy. olaparib 157-165 collagen type XI alpha 2 chain Homo sapiens 141-145 35568265-5 2022 Our studies in preclinical mouse models and ex vivo explants from breast cancer patients show that imipramine sensitizes TNBC to the PARP inhibitor olaparib and endocrine resistant ER + breast cancer to anti-estrogens. olaparib 148-156 collagen type XI alpha 2 chain Homo sapiens 133-137 35051747-2 2022 Until now, PARP inhibitors like olaparib are the first successful case of utilizing synthetic lethality-based therapy to treat cancers with DNA-repairing deficiency (e.g. BRCA1 or BRCA2 mutation), which has fueled the search for more targetable components in the DDR signaling pathway by exploiting synthetic lethality, including but not limited to DNA-PK, ATR, ATM, CHK1, and WEE1. olaparib 32-40 collagen type XI alpha 2 chain Homo sapiens 11-15 35169388-5 2022 When neoadjuvant therapy has failed to achieve the desired remission in BRCA1 and BRCA2 mutations, the administration of the PARP inhibitor olaparib has demonstrated an impressive response. olaparib 140-148 collagen type XI alpha 2 chain Homo sapiens 125-129 35200549-2 2022 In pancreatic ductal adenocarcinoma, the PARP inhibitor olaparib has recently been approved as maintenance treatment in patients with germline BRCA mutations reaching disease control after a platinum-based first line chemotherapy, proving significant benefit on progression free survival. olaparib 56-64 collagen type XI alpha 2 chain Homo sapiens 41-45 35096857-6 2021 The patient then received olaparib (a PARP inhibitor) + irinotecan and the disease stabilized for one year. olaparib 26-34 collagen type XI alpha 2 chain Homo sapiens 38-42 33742189-6 2021 Ongoing research to establish predictive biomarkers for the treatment of tumours with resistance to SG-ARAs led to the approval of the PARP inhibitors olaparib and rucaparib in pre-treated metastatic castration-resistant prostate cancer. olaparib 151-159 collagen type XI alpha 2 chain Homo sapiens 135-139 33722420-1 2021 The phase 3 PROfound trial led to the recent approval of the PARP inhibitor olaparib for men with metastatic castration-resistant prostate cancer and mutations in homologous recombination repair genes. olaparib 76-84 collagen type XI alpha 2 chain Homo sapiens 61-65 33722571-3 2021 Here, we show that ferroptosis, a form of regulated cell death driven by iron-dependent phospholipid peroxidation, is partly responsible for the efficacy of PARP inhibitor olaparib. olaparib 172-180 collagen type XI alpha 2 chain Homo sapiens 157-161 33984694-3 2021 The aim of our study was to combine ECT with PARP inhibitor olaparib, which could inhibit the repair of bleomycin or cisplatin induced DNA damage and potentiate the effectiveness of ECT. olaparib 60-68 collagen type XI alpha 2 chain Homo sapiens 45-49 33660437-3 2021 In a survey for potential combination therapies, we found that Wnt inhibition synergizes with the PARP inhibitor olaparib in Wnt-addicted cancers. olaparib 113-121 collagen type XI alpha 2 chain Homo sapiens 98-102 33012578-0 2021 Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib. olaparib 221-229 collagen type XI alpha 2 chain Homo sapiens 12-16 33012578-1 2021 The PROfound trial evaluated the PARP inhibitor olaparib in metastatic castration-resistant prostate cancers harboring alterations in BRCA1/2 and ATM (cohort A) and in 12 other homologous recombination repair genes (cohort B). olaparib 48-56 collagen type XI alpha 2 chain Homo sapiens 33-37 33012578-6 2021 PATIENT SUMMARY: A large clinical study concluded that treatment with the PARP inhibitor olaparib benefits men with metastatic castration-resistant prostate cancer whose tumors harbor alterations in 15 different DNA repair genes. olaparib 89-97 collagen type XI alpha 2 chain Homo sapiens 74-78 33091613-5 2021 Blocking a second antioxidant pathway (thioredoxin/thioredoxin reductase) using Auranofin or inhibiting DNA repair using the PARP inhibitor, Olaparib, led to significant increases in DSBs following Cyst(e)inase treatment in all PDAC cells examined. olaparib 141-149 collagen type XI alpha 2 chain Homo sapiens 125-129 33283705-0 2020 [Effects and Mechanism of PARP Inhibitor Olaparib on the Expression of NKG2D Ligands in HL-60 Cells]. olaparib 41-49 collagen type XI alpha 2 chain Homo sapiens 26-30 33261142-5 2020 We identified a synergistic action of these inhibitors with agents that produce DNA damage, like platinum compounds, gemcitabine, and the PARP inhibitor olaparib. olaparib 153-161 collagen type XI alpha 2 chain Homo sapiens 138-142 33271756-6 2020 Synergistic effects of DBF were observed in combination with PARP-inhibitor olaparib most likely due to the induction of ROS production by the marine alkaloid. olaparib 76-84 collagen type XI alpha 2 chain Homo sapiens 61-65 33152708-1 2020 BACKGROUND: Maintenance therapy with the PARP inhibitor olaparib for metastatic pancreatic cancer (MPC) with a germline BRCA1 or BRCA2 mutation has been shown to be effective. olaparib 56-64 collagen type XI alpha 2 chain Homo sapiens 41-45 32555285-5 2020 This study was conducted to investigate the anti-tumor effects of the WEE1 inhibitor, AZD1775, and the mechanism responsible for its potentiation of sensitivity to olaparib (a PARP inhibitor) via the modulation of DDR in TNBC cells. olaparib 164-172 collagen type XI alpha 2 chain Homo sapiens 176-180 32947941-8 2020 In estrogen receptor negative (ER-) breast cancer cells, combination of BOLD-100 with a PARP inhibitor, olaparib, induced significant inhibition of cell growth and xenografts and increased gamma-H2AX. olaparib 104-112 collagen type XI alpha 2 chain Homo sapiens 88-92 32948057-2 2020 Only recently, maintenance therapy with the PARP inhibitor olaparib showed improved progression-free survival in germline BRCA1/2-mutated PDAC patients after platinum-based induction for the first time. olaparib 59-67 collagen type XI alpha 2 chain Homo sapiens 44-48 32571788-5 2020 The effect of the PARP inhibitor olaparib was assessed in vitro, using cultured circulating tumor cells (CTCs) from a patient with a somatically acquired BRCA1 mutation and a second patient with an acquired BRCA2 mutation. olaparib 33-41 collagen type XI alpha 2 chain Homo sapiens 18-22 32778095-1 2020 BACKGROUND: Tumors with deficient homologous repair are sensitive to PARP inhibitors such as olaparib which is known to have immunogenic properties. olaparib 93-101 collagen type XI alpha 2 chain Homo sapiens 69-73 32041467-1 2020 Olaparib is a first-in-class PARP inhibitor that has demonstrated efficacy as maintenance therapy in patients with ovarian cancer. olaparib 0-8 collagen type XI alpha 2 chain Homo sapiens 29-33 32764580-8 2020 However, in contrast to other ROS-inducing agents, co-treatment with PARP-inhibitor olaparib revealed antagonistic effects indicating an active PARP to be necessary for MomC activity. olaparib 84-92 collagen type XI alpha 2 chain Homo sapiens 69-73 32764580-8 2020 However, in contrast to other ROS-inducing agents, co-treatment with PARP-inhibitor olaparib revealed antagonistic effects indicating an active PARP to be necessary for MomC activity. olaparib 84-92 collagen type XI alpha 2 chain Homo sapiens 144-148 31296812-1 2019 Recently, olaparib(brand name: Lynparza Tablets)-a PARP inhibitor-has been approved for national health insurance coverage in Japan as a drug for unresectable or recurrent, BRCA1/2-positive, HER2-negative breast cancer in patients with a history of cancer chemotherapy. olaparib 10-18 collagen type XI alpha 2 chain Homo sapiens 51-55 32249603-1 2020 Olaparib, an oral PARP-inhibitor, has shown clinical benefit for HER2-negative advanced breast cancer patients carrying a germinal BRCA1/2 mutation. olaparib 0-8 collagen type XI alpha 2 chain Homo sapiens 18-22 31877465-3 2020 Here we show similarities in the genotoxic effects of zebrafish and mammalian systems towards topoisomerase I (Top1) poisons and PARP inhibitor - olaparib. olaparib 146-154 collagen type XI alpha 2 chain Homo sapiens 129-133 32135515-4 2020 This report presents a case of a rare entire germline BRCA1 gene deletion and an exceptional response to a PARP inhibitor, olaparib, in a heavily pretreated patient with OC. olaparib 123-131 collagen type XI alpha 2 chain Homo sapiens 107-111 31031007-4 2019 Additional experiments identified the preclinical efficacy of combination olaparib PARP inhibitor and temozolomide DNA-damaging agent as an effective therapy for rhabdomyosarcoma and visualized therapeutic responses using a four-color FUCCI cell-cycle fluorescent reporter. olaparib 74-82 collagen type XI alpha 2 chain Homo sapiens 83-87 30725116-7 2019 IGFBP-3 complexes with NONO and SFPQ were blocked by inhibiting EGFR with gefitinib or DNA-PKcs with NU7026, and by the PARP inhibitors veliparib and olaparib, which also reduced DNA end-joining activity and delayed the resolution of the gammaH2AX signal (i.e. inhibited DNA DSB repair). olaparib 150-158 collagen type XI alpha 2 chain Homo sapiens 120-124 31101118-6 2019 RESULTS: In this work, we have studied the effect that VRK1 by itself or in collaboration with olaparib, an inhibitor of PARP, has on the DNA oxidative damage induced by irradiation in order to identify its potential as a new drug target. olaparib 95-103 collagen type XI alpha 2 chain Homo sapiens 121-125 30348635-1 2019 PURPOSE: It was recently demonstrated that the EWSR1-FLI1 t(11;22)(q24;12) translocation contributes to the hypersensitivity of Ewing sarcoma to PARP inhibitors, prompting clinical evaluation of olaparib in a cohort of heavily pretreated Ewing sarcoma tumors. olaparib 195-203 collagen type XI alpha 2 chain Homo sapiens 145-149 30660828-1 2019 Olaparib is a PARP inhibitor (PARPi). olaparib 0-8 collagen type XI alpha 2 chain Homo sapiens 14-18 30833416-5 2019 Single-agent treatment with the PARP inhibitor olaparib as well as subsequent combination with platinum-based chemotherapy resulted in disease stabilization and substantial improvement of clinical symptoms. olaparib 47-55 collagen type XI alpha 2 chain Homo sapiens 32-36 30682083-8 2019 The set of 84 predicted drug combinations for example holds the combination of the PARP inhibitor olaparib and paclitaxel, which showed efficacy in phase II clinical studies. olaparib 98-106 collagen type XI alpha 2 chain Homo sapiens 83-87 30736840-11 2019 In addition, SPAG5-silenced cells were more sensitive to the PARP inhibitor (PARPi) olaparib. olaparib 84-92 collagen type XI alpha 2 chain Homo sapiens 61-65 29898896-8 2018 Whereas PARP inhibition with Olaparib was not as effective in Ishikawa cells expressing native or PTEN-NLS, inhibition with Talazoparib was not affected by PTEN overexpression. olaparib 29-37 collagen type XI alpha 2 chain Homo sapiens 8-12 30084837-1 2018 Purpose: Our goal was to evaluate the safety and toxicity of combining a PARP inhibitor, olaparib, with cetuximab and fractionated intensity-modulated radiotherapy for patients with locally advanced head and neck cancer and heavy smoking histories.Patients and Methods: Patients with >=10 packs/year history of smoking were treated with olaparib at doses ranging from 25-200 mg orally twice daily beginning approximately 10 days prior to initiation of and with concurrent radiation (69.3 Gy in 33 fractions) using a time-to-event continual reassessment method model. olaparib 89-97 collagen type XI alpha 2 chain Homo sapiens 73-77 29748182-11 2018 Finally, we observed maximum cytotoxicity to the PARP inhibitor olaparib in BRCA2-/- organoids, similar to responses observed in patients.Conclusions: The LuCaP PDX/organoid models provide an expansive, genetically characterized platform to investigate the mechanisms of pathogenesis as well as therapeutic responses and their molecular correlates in mCRPC. olaparib 64-72 collagen type XI alpha 2 chain Homo sapiens 49-53 30232143-4 2018 Furthermore, AZD3514 enhanced cellular sensitivity to a PARP inhibitor olaparib by blocking the DDR pathway in breast cancer cells. olaparib 71-79 collagen type XI alpha 2 chain Homo sapiens 56-60 30555227-1 2018 Background: PARP inhibitors, such as Olaparib, have advanced the treatment of ovarian cancer by providing patients with an effective and molecularly-targeted maintenance therapy. olaparib 37-45 collagen type XI alpha 2 chain Homo sapiens 12-16 30353044-1 2018 BACKGROUND: Olaparib (Lynparza ) is a PARP inhibitor approved for advanced BRCA-mutated (BRCAm) ovarian cancer. olaparib 12-20 collagen type XI alpha 2 chain Homo sapiens 38-42 30333000-3 2018 It is known that the PARP inhibitor, olaparib, has a significant synthetic lethal effect on tumors with BRCA 1/2 mutations, particularly in ovarian and breast cancer. olaparib 37-45 collagen type XI alpha 2 chain Homo sapiens 21-25 30057890-12 2018 Ongoing clinical trials into the ATR inhibitor AZD6738 plus radiation, and the phenotypically similar combination of AZD6738 and the PARP inhibitor olaparib, are likely to be key in ascertaining the toxicity profile of such combinations. olaparib 148-156 collagen type XI alpha 2 chain Homo sapiens 133-137 29983873-2 2018 Here, we show that synergistic toxic action in cancer cells of combinations of antitumor platinum drug carboplatin and effective PARP inhibitor olaparib is considerably improved if these combined drugs are encapsulated into liposomes. olaparib 144-152 collagen type XI alpha 2 chain Homo sapiens 129-133 29983873-6 2018 These results also suggest that the enhancement of the toxic effects of carboplatin by olaparib in cancer cells is a consequence of an accumulation of cytotoxic lesions in DNA due to the inhibition of repair of platinated DNA augmented by the synergistic action of olaparib as an effective PARP inhibitor. olaparib 87-95 collagen type XI alpha 2 chain Homo sapiens 290-294 28146604-1 2018 BACKGROUND AND PURPOSE: The PARP inhibitor olaparib has recently been approved for human use for the therapy of cancer. olaparib 43-51 collagen type XI alpha 2 chain Homo sapiens 28-32 29582690-2 2018 Olaparib (Lynparza ), an orally administered PARP inhibitor, demonstrated clinical benefit in a phase III trial for mutated BRCA-positive HER2 negative metastatic breast cancer. olaparib 0-8 collagen type XI alpha 2 chain Homo sapiens 45-49 29382645-1 2018 The FDA has approved olaparib, a PARP inhibitor, for use in patients with metastatic breast cancer who also carry a germline BRCA1 or BRCA2 mutation. olaparib 21-29 collagen type XI alpha 2 chain Homo sapiens 33-37 29465803-2 2018 Recent clinical studies show favorable results for the PARP inhibitor olaparib used as single agent for treatment of metastatic castration-resistant PCa. olaparib 70-78 collagen type XI alpha 2 chain Homo sapiens 55-59 28916476-7 2017 NAD+ supplementation prevented ATP depletion and cell death, while treatment with a PARP inhibitor, olaparib, preserved NAD+ and ATP levels but led to increased DNA double-strand breakage and did not prevent ascorbate-induced cell death. olaparib 100-108 collagen type XI alpha 2 chain Homo sapiens 84-88 29290761-1 2017 OlympiAD was a phase 3 randomized controlled trial of a PARP inhibitor olaparib for metastatic HER2 negative breast cancer patients harboring a BRCA mutation. olaparib 71-79 collagen type XI alpha 2 chain Homo sapiens 56-60 27617661-1 2016 BACKGROUND: In patients with platinum-sensitive recurrent serous ovarian cancer, maintenance monotherapy with the PARP inhibitor olaparib significantly improves progression-free survival versus placebo. olaparib 129-137 collagen type XI alpha 2 chain Homo sapiens 114-118 28454085-0 2017 Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer. olaparib 73-81 collagen type XI alpha 2 chain Homo sapiens 58-62 28454085-1 2017 BACKGROUND: The PARP inhibitor olaparib was recently granted Food and Drug Administration (FDA) accelerated approval in patients with advanced BRCA1/2 mutation ovarian cancer. olaparib 31-39 collagen type XI alpha 2 chain Homo sapiens 16-20 28512243-6 2017 Tumors expressing phosphomimetic Mre11 were more sensitive to the PARP inhibitor olaparib, compared with those expressing unphosphorylatable Mre11, suggesting that patients with elevated Plk1 expression might benefit from olaparib treatment. olaparib 81-89 collagen type XI alpha 2 chain Homo sapiens 66-70 28450425-2 2017 We have reported a phase II trial (TOPARP-A) of the PARP inhibitor olaparib in metastatic prostate cancer, demonstrating antitumor activity associating with homologous recombination DNA repair defects. olaparib 67-75 collagen type XI alpha 2 chain Homo sapiens 37-41 28450426-1 2017 Approximately 20% of metastatic prostate cancers harbor mutations in genes required for DNA repair by homologous recombination repair (HRR) such as BRCA2 HRR defects confer synthetic lethality to PARP inhibitors (PARPi) such as olaparib and talazoparib. olaparib 228-236 collagen type XI alpha 2 chain Homo sapiens 196-200 28395540-4 2017 Areas covered: Olaparib is one of the most widely investigated PARP inhibitors. olaparib 15-23 collagen type XI alpha 2 chain Homo sapiens 63-67 28323658-12 2017 PARP inhibitors are gradually being established for therapeutic purposes, with olaparib achieving breakthrough status for prostate cancer patients with BRCA1 and 2 and ATM mutations. olaparib 79-87 collagen type XI alpha 2 chain Homo sapiens 0-4 28138868-8 2017 A synergistic interaction was observed for combination treatment with RK-33 and the PARP inhibitor olaparib in BRCA1-proficient breast cancer, with the mean combination index ranging from 0.59 to 0.62. olaparib 99-107 collagen type XI alpha 2 chain Homo sapiens 84-88 27924011-10 2016 Furthermore, we show that low APRIN expression levels correlate with a better survival in ovarian cancer patients and that APRIN depletion sensitizes cells to the PARP inhibitor Olaparib in xenografted zebrafish. olaparib 178-186 collagen type XI alpha 2 chain Homo sapiens 163-167 27708239-7 2016 In cell culture models of BRCA1-mutant breast cancer, FOXC1 is associated with increased proliferation and may serve as a marker for sensitivity to PARP-inhibitor therapy with olaparib. olaparib 176-184 collagen type XI alpha 2 chain Homo sapiens 148-152 27065456-4 2016 The first PARP inhibitor, olaparib, has now been licensed for BRCA-mutated ovarian cancers. olaparib 26-34 collagen type XI alpha 2 chain Homo sapiens 10-14 26961146-1 2016 BACKGROUND: The PARP inhibitor olaparib (Lynparza ) demonstrates antitumor activity in women with relapsed ovarian cancer and a germline BRCA1/2 mutation (gBRCAm). olaparib 31-39 collagen type XI alpha 2 chain Homo sapiens 16-20 27345073-1 2016 PURPOSE: The PARP inhibitor, Olaparib, is approved for women with BRCA-mutated ovarian cancer. olaparib 29-37 collagen type XI alpha 2 chain Homo sapiens 13-17 26899229-0 2016 Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer. olaparib 38-46 collagen type XI alpha 2 chain Homo sapiens 50-54 26934368-9 2016 The PARP inhibitors, olaparib and niraparib, increased the extent of persistent DNA damage induced by radiation exposure as well as the extent of both autophagy and senescence. olaparib 21-29 collagen type XI alpha 2 chain Homo sapiens 4-8 26909613-0 2016 Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer. olaparib 58-66 collagen type XI alpha 2 chain Homo sapiens 43-47 26909613-1 2016 Recent preclinical studies revealed the efficacy of combined use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib in breast and prostate cancers. olaparib 109-117 collagen type XI alpha 2 chain Homo sapiens 94-98 26310895-5 2015 In addition, these compounds exacerbate DNA damage and cell death in response to the PARP inhibitor olaparib in BRCA2-deficient Capan-1 cells and cooperate with gemcitabine to the killing of pancreatic cancer cells. olaparib 100-108 collagen type XI alpha 2 chain Homo sapiens 85-89 26961668-3 2016 In the United States, Olaparib, a PARP inhibitor, has been recently approved for ovarian cancer patients treated with three or more lines of prior chemotherapy who harbor germline mutations in BRCA1 or BRCA2. olaparib 22-30 collagen type XI alpha 2 chain Homo sapiens 34-38 26303225-1 2015 PURPOSE: To determine the cost-effectiveness of olaparib, a PARP inhibitor, as maintenance therapy for platinum-sensitive (PS) recurrent ovarian cancer. olaparib 48-56 collagen type XI alpha 2 chain Homo sapiens 60-64 26510020-2 2015 We hypothesized that metastatic, castration-resistant prostate cancers with DNA-repair defects would respond to poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibition with olaparib. olaparib 187-195 collagen type XI alpha 2 chain Homo sapiens 165-169 26510020-12 2015 CONCLUSIONS: Treatment with the PARP inhibitor olaparib in patients whose prostate cancers were no longer responding to standard treatments and who had defects in DNA-repair genes led to a high response rate. olaparib 47-55 collagen type XI alpha 2 chain Homo sapiens 32-36 25981132-0 2015 Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells. olaparib 51-59 collagen type XI alpha 2 chain Homo sapiens 36-40 25981132-1 2015 BACKGROUND AND PURPOSE: The PARP inhibitor olaparib is currently tested in clinical phase 1 trials to define safe dose levels in combination with RT. olaparib 43-51 collagen type XI alpha 2 chain Homo sapiens 28-32 25975349-6 2015 Inhibition of autophagy by gene knockdown significantly diminished AZD2281-induced mitophagy and apoptosis, indicating that autophagic process mediates some of the downstream effects of PARP inhibitors. olaparib 67-74 collagen type XI alpha 2 chain Homo sapiens 186-190 25975349-0 2015 The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells. olaparib 19-26 collagen type XI alpha 2 chain Homo sapiens 4-8 25975349-0 2015 The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells. olaparib 28-36 collagen type XI alpha 2 chain Homo sapiens 4-8 25975349-2 2015 In this study, we investigated the antiproliferative effects and mechanism of PARP inhibitors ABT-888 (Veliparib), BSI-201 (Iniparib) and AZD228 (Olaparib) in breast cancer cell lines with BRCA1 or BRCA2 mutations and 9 different BRCA wild-type cell lines with BRCA1 allelic loss. olaparib 146-154 collagen type XI alpha 2 chain Homo sapiens 78-82 25975349-3 2015 We found that AZD2281 was the most potent in the PARP inhibitors and induces significant growth inhibition (~95%) in BRCA1 mutant (HCC-1937, MDA-MB-436, and SUM-149PT) and BRCA2 mutant (HCC-1428) cell lines. olaparib 14-21 collagen type XI alpha 2 chain Homo sapiens 49-53 25975349-7 2015 In conclusion, our data provide the first evidence of PARP inhibitor AZD2281 autophagy and mitophagy in breast cancer cell lines with BRCA mutations or BRCA-allelic loss. olaparib 69-76 collagen type XI alpha 2 chain Homo sapiens 54-58 25583815-1 2015 In a phase II study, researchers found that the PARP inhibitor olaparib led to stable disease or tumor regressions in patients with advanced breast, ovarian, pancreatic, and prostate cancers who had germline mutations in BRCA1 or BRCA2. olaparib 63-71 collagen type XI alpha 2 chain Homo sapiens 48-52 26095524-8 2015 Finally, potent synergy between XI-006 and olaparib (PARP inhibitor) were observed due to the down-regulation of Mre11. olaparib 43-51 collagen type XI alpha 2 chain Homo sapiens 53-57 25758301-8 2015 Olaparib, a PARP inhibitor, has only been evaluated in one study in metastatic patients, with promising results. olaparib 0-8 collagen type XI alpha 2 chain Homo sapiens 12-16 25404465-2 2015 Olaparib is a potent new generation PARP inhibitor that has been approved for human testing. olaparib 0-8 collagen type XI alpha 2 chain Homo sapiens 36-40 26097887-2 2015 Inhibitors of DNA repair enzymes including APE1, ATM, ATR, DNA-PK and PARP have been developed and the PARP inhibitor olaparib is the first-in-class approved in Europe and the USA for the treatment of advanced BRCA-mutated ovarian cancer. olaparib 118-126 collagen type XI alpha 2 chain Homo sapiens 70-74 26097887-2 2015 Inhibitors of DNA repair enzymes including APE1, ATM, ATR, DNA-PK and PARP have been developed and the PARP inhibitor olaparib is the first-in-class approved in Europe and the USA for the treatment of advanced BRCA-mutated ovarian cancer. olaparib 118-126 collagen type XI alpha 2 chain Homo sapiens 103-107 25634209-7 2015 UNC0638, a small-molecule inhibitor of histone lysine methyltransferase (HKMT), abolished retention and cooperated with the PARP inhibitor olaparib to block cancer cell growth. olaparib 139-147 collagen type XI alpha 2 chain Homo sapiens 124-128 26312527-3 2015 We have investigated the dose- and time-dependency of cell growth, cell death and cell cycle traverse of 4 malignant lymphocyte cell lines treated with the PARP inhibitor Olaparib. olaparib 171-179 collagen type XI alpha 2 chain Homo sapiens 156-160 23570906-5 2013 To investigate this, we performed a high throughput miRNA mimetic screen, which identified several miRNAs whose over-expression results in sensitization to the clinical PARP inhibitor olaparib. olaparib 184-192 collagen type XI alpha 2 chain Homo sapiens 169-173 24748377-6 2014 Ovarian tumors deficient in Brca1 respond to treatment with cisplatin and olaparib, a PARP inhibitor, whereas Brca1-wild type tumors are non-responsive to treatment, recapitulating the relative sensitivities observed in patients. olaparib 74-82 collagen type XI alpha 2 chain Homo sapiens 86-90 23966292-9 2013 Interestingly, EGFR-mutant cells treated with the PARP inhibitor olaparib also displayed decreased FAN1 foci induction, coupled with a putative block in a late HRR step. olaparib 65-73 collagen type XI alpha 2 chain Homo sapiens 50-54 23847380-1 2013 A phase II study of the PARP inhibitor olaparib (AstraZeneca) for cancer patients with inherited BRCA1 and BRCA2 gene mutations confirmed earlier results showing clinical benefit for advanced breast and ovarian cancers, and demonstrated evidence of effectiveness against pancreatic and prostate cancers. olaparib 39-47 collagen type XI alpha 2 chain Homo sapiens 24-28 25302077-10 2014 Further, the CGI between budding/fission yeast msh2 and SUMO-protease Ulp2 is maintained in human cells (MSH2/SENP6), and enhanced by Olaparib, a PARP inhibitor that induces the accumulation of single-strand DNA breaks. olaparib 134-142 collagen type XI alpha 2 chain Homo sapiens 146-150 25025963-1 2014 BACKGROUND: Olaparib, an oral PARP inhibitor, has shown antitumour activity as monotherapy in patients with germline BRCA1/2 (gBRCA)-mutated breast and ovarian cancer. olaparib 12-20 collagen type XI alpha 2 chain Homo sapiens 30-34 24534203-1 2014 In this study, we explored the antitumor activities of the PARP inhibitor AZD2281 (Olaparib) and the pan-Bcl-2 inhibitor GX15-070 (Obatoclax) in six pancreatic cancer cell lines. olaparib 74-81 collagen type XI alpha 2 chain Homo sapiens 59-63 24632590-3 2014 Here, we demonstrate that three PARP drug candidates, namely, rucaparib, veliparib, and olaparib, have a clearly different in vitro affinity profile across a panel of diverse kinases selected using a computational approach that relates proteins by ligand similarity. olaparib 88-96 collagen type XI alpha 2 chain Homo sapiens 32-36 24784564-4 2014 We show, for the first time, that IDO mediates human tumor cell resistance to a PARP inhibitor (olaparib), gamma radiation, cisplatin, and combined treatment with olaparib and radiation, in the absence of immune cells. olaparib 96-104 collagen type XI alpha 2 chain Homo sapiens 80-84 23415752-6 2013 The cytotoxicity of PARP inhibitors olaparib and veliparib was examined in 20 cell lines. olaparib 36-44 collagen type XI alpha 2 chain Homo sapiens 20-24 23239809-3 2013 We hypothesize that PTEN-deficient lung cancer cells suppressed DNA damage signaling and that the absence of PTEN can sensitize these cells to a concurrent treatment of a DNA-damaging agent (cisplatin) and a PARP inhibitor (olaparib). olaparib 224-232 collagen type XI alpha 2 chain Homo sapiens 208-212 22933245-6 2012 Importantly, the combination of a NAMPT small molecule inhibitor, FK866, with olaparib inhibited TN breast tumour growth in vivo to a greater extent than either single agent alone suggesting that assessing NAMPT/PARP inhibitor combinations for the treatment of TN breast cancer may be warranted. olaparib 78-86 collagen type XI alpha 2 chain Homo sapiens 212-216 22915752-5 2012 In TNBC patient-derived primary tumor xenografts, dual PI3K and PARP inhibition with BKM120 and olaparib reduced the growth of tumors displaying BRCA1/2 downregulation following PI3K inhibition. olaparib 96-104 collagen type XI alpha 2 chain Homo sapiens 64-68 22987487-5 2012 HER2 overexpression in HER2 negative breast cancer cells was sufficient to render cells susceptible to the PARP inhibitors ABT-888 and AZD-2281 both in vitro and in vivo, which was abrogated by HER2 reduction. olaparib 135-143 collagen type XI alpha 2 chain Homo sapiens 107-111 21600381-3 2011 Agents in development include inhibitors of the poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) pathway, such as iniparib, olaparib, and veliparib; the PI3K/Akt/mTOR pathway inhibitor everolimus; and the Src family tyrosine kinase inhibitor dasatinib. olaparib 134-142 collagen type XI alpha 2 chain Homo sapiens 101-105 22562176-1 2012 Synthetic lethal therapeutic strategy using poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor olaparib in carriers of BRCA1 or BRCA2 mutation has shown promise in clinical settings. olaparib 113-121 collagen type XI alpha 2 chain Homo sapiens 97-101 22562176-6 2012 The concept of synthetic lethal therapeutic strategy with the BRCA1 inhibitor 2 and the PARP inhibitor Olaparib was explored in HeLa, MDA-MB-231, and HCC1937 cell lines. olaparib 103-111 collagen type XI alpha 2 chain Homo sapiens 88-92 19589159-16 2009 The importance of these findings lies in the potential benefit from targeted therapy, through the use of agents leading to DNA double-strand breaks such as PARP inhibitors (olaparib) and cisplatin, for a much larger group of patients than the few BRCA1 and BRCA2 germline mutation carriers. olaparib 173-181 collagen type XI alpha 2 chain Homo sapiens 156-160 20976249-7 2010 Swi5(-/-) and Sfr1(-/-) cells are selectively sensitive to agents that cause DNA strand breaks, in particular ionizing radiation, camptothecin, and the Parp inhibitor olaparib. olaparib 167-175 collagen type XI alpha 2 chain Homo sapiens 152-156 20922827-0 2010 Targeted therapies: PARP inhibitor olaparib is safe and effective in patients with BRCA1 and BRCA2 mutations. olaparib 35-43 collagen type XI alpha 2 chain Homo sapiens 20-24